Van ECK Associates Corp boosted its holdings in shares of Agilent Technologies Inc (NYSE:A) by 35.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,226 shares of the medical research company’s stock after acquiring an additional 323 shares during the quarter. Van ECK Associates Corp’s holdings in Agilent Technologies were worth $83,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in A. Robeco Institutional Asset Management B.V. boosted its position in Agilent Technologies by 6.4% during the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 172,434 shares of the medical research company’s stock worth $12,164,000 after acquiring an additional 10,419 shares during the period. Cambridge Investment Research Advisors Inc. raised its stake in shares of Agilent Technologies by 18.1% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 12,053 shares of the medical research company’s stock worth $850,000 after purchasing an additional 1,850 shares in the last quarter. Bessemer Group Inc. raised its stake in shares of Agilent Technologies by 2,945.2% during the 3rd quarter. Bessemer Group Inc. now owns 5,390 shares of the medical research company’s stock worth $380,000 after purchasing an additional 5,213 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in shares of Agilent Technologies by 1.4% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,028,152 shares of the medical research company’s stock worth $72,526,000 after purchasing an additional 14,483 shares in the last quarter. Finally, Toronto Dominion Bank raised its stake in shares of Agilent Technologies by 0.7% during the 3rd quarter. Toronto Dominion Bank now owns 207,413 shares of the medical research company’s stock worth $14,627,000 after purchasing an additional 1,354 shares in the last quarter.

In other Agilent Technologies news, CEO Michael R. Mcmullen sold 17,491 shares of Agilent Technologies stock in a transaction that occurred on Wednesday, January 30th. The stock was sold at an average price of $75.00, for a total value of $1,311,825.00. Following the transaction, the chief executive officer now directly owns 456,430 shares of the company’s stock, valued at approximately $34,232,250. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Dominique Grau sold 8,902 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, February 12th. The stock was sold at an average price of $77.00, for a total value of $685,454.00. Following the sale, the insider now directly owns 103,387 shares in the company, valued at approximately $7,960,799. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 74,171 shares of company stock worth $5,764,185.

A number of equities research analysts have recently weighed in on A shares. Alembic Global Advisors downgraded Agilent Technologies to a “hold” rating in a research note on Monday, December 31st. Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a research note on Monday, January 21st. Needham & Company LLC started coverage on Agilent Technologies in a research note on Wednesday, January 2nd. They set a “buy” rating and a $77.00 price target for the company. JPMorgan Chase & Co. raised their price target on Agilent Technologies to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, February 21st. Finally, UBS Group started coverage on Agilent Technologies in a research note on Friday. They set a “buy” rating and a $92.00 price target for the company. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $86.91.

Shares of A stock opened at $81.10 on Friday. The company has a current ratio of 3.39, a quick ratio of 2.79 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $25.75 billion, a P/E ratio of 29.07, a P/E/G ratio of 2.22 and a beta of 1.38. Agilent Technologies Inc has a twelve month low of $60.42 and a twelve month high of $81.76.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.76 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. Agilent Technologies had a return on equity of 19.90% and a net margin of 22.86%. The company’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.66 EPS. On average, research analysts forecast that Agilent Technologies Inc will post 3.06 EPS for the current year.

Agilent Technologies announced that its Board of Directors has authorized a stock buyback program on Monday, November 19th that permits the company to buyback $1.75 billion in outstanding shares. This buyback authorization permits the medical research company to buy up to 8.8% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its shares are undervalued.

WARNING: This article was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.mareainformativa.com/news/2019/03/17/van-eck-associates-corp-increases-holdings-in-agilent-technologies-inc-a.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: What is the S&P 500 Index?

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).

Institutional Ownership by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.